Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Brazil's agricultural research agency gets cannabis research greenlight21.11.2025 - 2Manual for Famous people Known for Their Altruistic Endeavors01.01.1
- 3A photographer finds thousands of dinosaur footprints near Italian Winter Olympic venue16.12.2025
- 415 Outrageous Cosplay Outfits That Will Blow You Away04.12.2015
- 5Unsold Rams May Be Less expensive Than You Suspect06.11.2023
- The Most Enrapturing Authentic Milestones to Visit
- Sea Ice Hits New Low in Hottest Year on Record for the Arctic
- Tire Brands for Senior Drivers: Guaranteeing Security and Solace
- Novartis to build manufacturing hub in North Carolina, creating 700 jobs
- All the eclipses, supermoons, meteor showers and planets to spot in 2026
- Astronomers discover never-before-seen celestial object: "Cloud 9"
- When fake data is a good thing – how synthetic data trains AI to solve real problems
- These Cities Led Global Jet-Setting In 2025, According To New Data
- Figure out how to Detect the Best Rooftop Substitution Choices
